Organon & Co (OGN)
18.07
-0.71
(-3.78%)
USD |
NYSE |
Nov 01, 16:00
18.02
-0.05
(-0.28%)
After-Hours: 20:00
Organon Revenue (Quarterly): 1.582B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.582B |
| June 30, 2024 | 1.607B |
| March 31, 2024 | 1.622B |
| December 31, 2023 | 1.598B |
| September 30, 2023 | 1.519B |
| June 30, 2023 | 1.608B |
| March 31, 2023 | 1.538B |
| December 31, 2022 | 1.485B |
| September 30, 2022 | 1.537B |
| June 30, 2022 | 1.585B |
| Date | Value |
|---|---|
| March 31, 2022 | 1.567B |
| December 31, 2021 | 1.603B |
| September 30, 2021 | 1.60B |
| June 30, 2021 | 1.595B |
| March 31, 2021 | 1.506B |
| December 31, 2020 | 1.613B |
| September 30, 2020 | 1.613B |
| June 30, 2020 | 1.526B |
| March 31, 2020 | 1.78B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.485B
Minimum
Dec 2022
1.78B
Maximum
Mar 2020
1.583B
Average
1.595B
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 11.44B |
| Biomarin Pharmaceutical Inc | 745.74M |
| Cassava Sciences Inc | -- |
| Ligand Pharmaceuticals Inc | 41.53M |
| TG Therapeutics Inc | 73.47M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 359.00M |
| Total Expenses (Quarterly) | 1.192B |
| EPS Diluted (Quarterly) | 1.38 |
| Enterprise Value | 12.64B |
| Gross Profit Margin (Quarterly) | 58.34% |
| Profit Margin (Quarterly) | 22.69% |
| Earnings Yield | 27.89% |
| Operating Earnings Yield | 32.18% |
| Normalized Earnings Yield | 31.18 |